secwatch.observer — SEC 8-K summary
======================================

Issuer:     Microbot Medical Inc. (MBOT)
CIK:        0000883975
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001493152-26-019775
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Microbot Medical appoints Alon Tamir VP Sales EMEA, targets CE mark by end of 2026
--------------------------------------------------------------------------------

- Alon Tamir named Vice President of Sales for Europe, Middle East and Asia (EMEA) to lead international expansion.
- Company expects CE mark approval by end of 2026; leveraging FDA clearance received September 2025.
- Europe has approximately 2.3 million peripheral endovascular procedures annually, comparable to U.S. market size.
- LIBERTY Endovascular Robotic System is in full market release in the U.S. after limited market release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/883975/000149315226019775/0001493152-26-019775-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/883975/000149315226019775/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-019775

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer